131 related articles for article (PubMed ID: 38714773)
1. Comparison of preventive effects of combined furosemide and mannitol versus single diuretics, furosemide or mannitol, on cisplatin-induced nephrotoxicity.
Takagi A; Miyoshi T; Hayashi T; Koizumi H; Tsumagari K; Yokota C; Nakano T; Matsuo K; Egawa T
Sci Rep; 2024 May; 14(1):10511. PubMed ID: 38714773
[TBL] [Abstract][Full Text] [Related]
2. A retrospective evaluation of furosemide and mannitol for prevention of cisplatin-induced nephrotoxicity.
Mach CM; Kha C; Nguyen D; Shumway J; Meaders KM; Ludwig M; Williams-Brown MY; Anderson ML
J Clin Pharm Ther; 2017 Jun; 42(3):286-291. PubMed ID: 28276070
[TBL] [Abstract][Full Text] [Related]
3. Furosemide versus mannitol in Japanese patients with thoracic malignancy who received cisplatin-based chemotherapy using short hydration: study protocol for a randomised controlled trial.
Murakami E; Akamatsu H; Shimokawa T; Wada K; Yamamoto N
BMJ Open; 2019 Dec; 9(12):e029057. PubMed ID: 31831529
[TBL] [Abstract][Full Text] [Related]
4. Risk Factors for Cisplatin-Induced Nephrotoxicity: A Multicenter Retrospective Study.
Miyoshi T; Uoi M; Omura F; Tsumagari K; Maesaki S; Yokota C
Oncology; 2021; 99(2):105-113. PubMed ID: 32966986
[TBL] [Abstract][Full Text] [Related]
5. Saline, mannitol, and furosemide hydration in acute cisplatin nephrotoxicity: a randomized trial.
Santoso JT; Lucci JA; Coleman RL; Schafer I; Hannigan EV
Cancer Chemother Pharmacol; 2003 Jul; 52(1):13-8. PubMed ID: 12719883
[TBL] [Abstract][Full Text] [Related]
6. Preventive effect of 20 mEq and 8 mEq magnesium supplementation on cisplatin-induced nephrotoxicity: a propensity score-matched analysis.
Miyoshi T; Hayashi T; Uoi M; Omura F; Tsumagari K; Maesaki S; Yokota C; Nakano T; Egawa T
Support Care Cancer; 2022 Apr; 30(4):3345-3351. PubMed ID: 34984552
[TBL] [Abstract][Full Text] [Related]
7. Randomized study comparing mannitol with furosemide for the prevention of cisplatin-induced renal toxicity in non-small cell lung cancer: The OLCSG1406 trial.
Makimoto G; Hotta K; Oze I; Ninomiya K; Nakanishi M; Hara N; Kano H; Watanabe H; Hata Y; Nishii K; Nakasuka T; Itano J; Ninomiya T; Kubo T; Ohashi K; Ichihara E; Minami D; Sato A; Tabata M; Maeda Y; Kiura K
Asia Pac J Clin Oncol; 2021 Feb; 17(1):101-108. PubMed ID: 32885583
[TBL] [Abstract][Full Text] [Related]
8. Evaluation of the effect of acetazolamide versus mannitol on cisplatin-induced nephrotoxicity, a pilot study.
El Hamamsy M; Kamal N; Bazan NS; El Haddad M
Int J Clin Pharm; 2018 Dec; 40(6):1539-1547. PubMed ID: 30167970
[TBL] [Abstract][Full Text] [Related]
9. Mannitol for the prevention of cisplatin-induced nephrotoxicity: A retrospective comparison of hydration plus mannitol versus hydration alone in inpatient and outpatient regimens at a large academic medical center.
Williams RP; Ferlas BW; Morales PC; Kurtzweil AJ
J Oncol Pharm Pract; 2017 Sep; 23(6):422-428. PubMed ID: 27352615
[TBL] [Abstract][Full Text] [Related]
10. Comparison of oral and intravenous hydration and diuretic, choice for protecting cisplatin induced nephrotoxicity.
Dana R; Kachhwaha VS
Indian J Cancer; 1996 Dec; 33(4):168-70. PubMed ID: 9254992
[TBL] [Abstract][Full Text] [Related]
11. [Experimental studies on the nephrotoxicity of cisplatin--amelioration of nephrotoxicity by continuous infusion].
Izumi T
Hinyokika Kiyo; 1988 Jan; 34(1):37-45. PubMed ID: 3132030
[TBL] [Abstract][Full Text] [Related]
12. A comparison of the rates of cisplatin (cDDP)--induced nephrotoxicity associated with sodium loading or sodium loading with forced diuresis as a preventative measure.
Leu L; Baribeault D
J Oncol Pharm Pract; 2010 Sep; 16(3):167-71. PubMed ID: 19759050
[TBL] [Abstract][Full Text] [Related]
13. Mannitol to prevent cisplatin-induced nephrotoxicity in patients with squamous cell cancer of the head and neck (SCCHN) receiving concurrent therapy.
McKibbin T; Cheng LL; Kim S; Steuer CE; Owonikoko TK; Khuri FR; Shin DM; Saba NF
Support Care Cancer; 2016 Apr; 24(4):1789-93. PubMed ID: 26446698
[TBL] [Abstract][Full Text] [Related]
14. [Can cisplatin renal toxicity be prevented?].
Brillet G; Deray G; Bunker D; Ben Hmida M; Baumelou A; Jacobs C
Nephrologie; 1991; 12(3):143-6. PubMed ID: 1922654
[TBL] [Abstract][Full Text] [Related]
15. A case-control study analyzing mannitol dosing for prevention of cisplatin-induced acute nephrotoxicity.
Dhillon P; Amir E; Lo M; Kitchlu A; Chan C; Cochlin S; Yip P; Chen E; Lee R; Ng P
J Oncol Pharm Pract; 2019 Jun; 25(4):875-883. PubMed ID: 29722605
[TBL] [Abstract][Full Text] [Related]
16. The renal clearance of unchanged cisplatin during furosemide and mannitol diuresis is dependent on glomerular filtration rate in rats.
Nagai N; Ogata H
J Pharm Sci; 1996 Jul; 85(7):720-4. PubMed ID: 8818996
[TBL] [Abstract][Full Text] [Related]
17. Randomized Phase II Study Comparing Mannitol with Furosemide for the Prevention of Renal Toxicity Induced by Cisplatin-based Chemotherapy with Short-term Low-volume Hydration in Advanced Non-small Cell Lung Cancer: The OLCSG1406 Study Protocol.
Makimoto G; Ichihara E; Hotta K; Ninomiya K; Oze I; Minami D; Ninomiya T; Kubo T; Ohashi K; Tabata M; Maeda Y; Kiura K
Acta Med Okayama; 2018 Jun; 72(3):319-323. PubMed ID: 29926012
[TBL] [Abstract][Full Text] [Related]
18. Cisplatin-induced nephrotoxicity in children: what is the best protective strategy?
Ruggiero A; Ariano A; Triarico S; Capozza MA; Romano A; Maurizi P; Mastrangelo S; Attinà G
J Oncol Pharm Pract; 2021 Jan; 27(1):180-186. PubMed ID: 32990190
[TBL] [Abstract][Full Text] [Related]
19. Co-administration of proton pump inhibitors ameliorates nephrotoxicity in patients receiving chemotherapy with cisplatin and fluorouracil: a retrospective cohort study.
Ikemura K; Oshima K; Enokiya T; Okamoto A; Oda H; Mizuno T; Ishinaga H; Muraki Y; Iwamoto T; Takeuchi K; Katayama N; Okuda M
Cancer Chemother Pharmacol; 2017 May; 79(5):943-949. PubMed ID: 28364288
[TBL] [Abstract][Full Text] [Related]
20. The Effect of Intravenous Mannitol Combined With Normal Saline in Preventing Cisplatin-Induced Nephrotoxicity: A Randomized, Double-Blind, Placebo-Controlled Trial.
Sainamthip P; Saichaemchan S; Satirapoj B; Prasongsook N
JCO Glob Oncol; 2022 Mar; 8():e2100275. PubMed ID: 35436142
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
